drugset

drugset / Trial / NCT00003820

Rituximab in Treating Patients With Hodgkin's Lymphoma

NCT00003820 ↗

Phase 2 Completed 39 enrolled Ranjana Advani Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.

Timeline

Start: 1999-01
Primary completion: 2008-08
Completion: 2008-08

Outcome

Missed primary endpoint

paper R + MR results in a nonsignificant increase in PFS compared with R. PMID 24516013 ↗

Publications

Results Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014 Mar 20;32(9):912-8. doi: 10.1200/JCO.2013.53.2069. Epub 2014 Feb 10.
Results Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood [ASH Annual Meeting Abstracts]. 2007;110:abs644.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Indications